Overview

Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive cardiorenal-metabolic syndrome characterized by hyperglycemia resulting from a complex interplay of insulin resistance in peripheral tissues (muscle, liver, adipose) and a relative (progressing to absolute) deficiency in insulin secretion from pancreatic beta-cells.

It is the most common form of diabetes, accounting for > 90% of cases. Historically termed "adult-onset" or "non-insulin dependent" diabetes, these terms are now obsolete due to the rising prevalence in children/adolescents and the frequent eventual need for insulin therapy in the natural history of the disease.

Current management paradigms have shifted from a glucocentric focus (lowering HbA1c to prevent microvascular complications) to a holistic cardiorenal approach (using disease-modifying agents like SGLT2i and GLP-1 RAs to prevent heart failure, renal progression, and cardiovascular death, independent of glycemic control). Furthermore, the landmark DiRECT trial has established T2DM as a potentially reversible condition in its early stages through significant weight loss.

Epidemiology

Prevalence

T2DM is a global health emergency.

• Global Burden: Estimated to affect 537 million adults (1 in 10) worldwide in 2021, projected to rise to 783 million by 2045.
• UK Context: Over 4.3 million people live with a diagnosis of diabetes in the UK, with another 850,000 estimated to have undiagnosed T2DM.
• Economic Impact: Diabetes accounts for ~10% of the entire NHS budget, with 80% of costs attributable to treating potentially preventable complications.

Demographic Trends

• Age: Prevalence increases with age, peaking at 20% in those over 65.
• Early-Onset T2DM: Diagnosed less than 40 years. This phenotype is more aggressive, with faster beta-cell decline, earlier complications, and higher mortality than late-onset disease.
• Gender: Slightly higher prevalence in men.

Risk Factors

Non-Modifiable

• Family History: First-degree relative (x3 risk).
• Genetics: Highly heritable (up to 70% concordance in monozygotic twins). Key variants: TCF7L2 (beta-cell function), FTO (obesity).
• Ethnicity:
  • South Asian, Black African, African Caribbean: 2-4x higher risk compared to White Europeans.
  • Onset is often 10-15 years earlier.
  • Mechanism: "Thin-fat" phenotype (more visceral fat for a given BMI).
• Gestational Diabetes (GDM): 7-fold increased lifetime risk.

Modifiable

• Obesity: The strongest risk factor.
  • Visceral Adiposity: Waist circumference is a better predictor than BMI.
    • Men: > 94cm (High risk > 102cm).
    • Women: > 80cm (High risk > 88cm).
    • South Asian Men: > 90cm.
• Physical Inactivity: Independently reduces insulin sensitivity.
• Diet: High glycemic load, low fiber, ultra-processed foods.
• Metabolic Syndrome: Cluster of Hypertension, Dyslipidemia (High Trigs, Low HDL), and Central Obesity.
• PCOS: Polycystic Ovary Syndrome is an insulin-resistant state.
• Depression/Schizophrenia: Associated with poor lifestyle + diabetogenic antipsychotics (Olanzapine/Clozapine).

Pathophysiology: The "Egregious Eleven"

Professor Ralph DeFronzo initially described the "Triumvirate" (Beta-cell, Muscle, Liver), then the "Ominous Octet". The current model is the "Egregious Eleven", describing 11 distinct organ-specific defects driving hyperglycemia.

[!NOTE] "Starling's Curve of the Pancreas" In the early stages (Insulin Resistance), beta-cells compensate by hypersecreting insulin (Hyperinsulinemia). Over time, they fail ("Beta-cell burnout"), leading to relative deficiency and hyperglycemia. Treatment must address both resistance (Metformin/Glitazones) and secretion/replacement (Incretins/Insulin).

Diagnosis

Diagnostic Criteria (WHO 2011)

Diagnosis relies on establishing persistent hyperglycemia. Standard: HbA1c (Glycated Hemoglobin). Alternative: Fasting Plasma Glucose (FPG) or Oral Glucose Tolerance Test (OGTT).

The Diagnostic Thresholds

Guidelines for Diagnosis

1. Symptomatic Patient: A single abnormal test result confirms diagnosis.
   • Classic Symptoms: Polyuria, polydipsia, weight loss, blurred vision, thrush.
2. Asymptomatic Patient: Requires two abnormal test results on separate days.
   • Ideally repeat the same test (e.g., HbA1c then repeat HbA1c).
   • If concordance exists between two different tests (e.g., HbA1c > 48 AND FPG > 7.0), diagnosis is confirmed.

Situations Where HbA1c is Invalid

HbA1c relies on normal red blood cell (RBC) turnover (~120 days). Do NOT use HbA1c if:

• Rapid Onset Suspicion: T1DM in children/young adults (glucose rises faster than HbA1c).
• Pregnancy: Physiological changes in turnover.
• Hemoglobinopathies: Sickle Cell, Thalassemia (variants interfere with assay).
• Anemia / Hemolysis:
  • Iron/B12 Deficiency: Increases RBC lifespan -> Falsely HIGH HbA1c.
  • Hemolysis/Blood Loss: Decreases RBC lifespan -> Falsely LOW HbA1c.
• Chronic Kidney Disease (ESRD): Erythropoietin injections alter turnover.

Differential Diagnosis: T1DM vs T2DM vs LADA

Differentiating Type 1 from Type 2 is critical as T1DM requires immediate life-saving insulin.

C-Peptide Interpretation

C-Peptide provides a stable measure of endogenous insulin secretion. It should be measured when the diagnosis is uncertain (e.g., lean adult, rapid failure of oral agents).

• Interpretation (with concurrent hyperglycemia > 8 mmol/L):
  • less than 200 pmol/L: Absolute deficiency. Type 1 Diabetes.
  • 200 - 600 pmol/L: Borderline. Likely significant deficiency (LADA/T1DM).
  • > 600 pmol/L: Significant reserve. Type 2 Diabetes (Insulin Resistance).

Autoantibodies

• Anti-GAD65 (Glutamic Acid Decarboxylase): Most common in adults (LADA).
• Anti-IA2 (Tyrosine Phosphatase): More specific for classic T1DM.
• Anti-ZnT8 (Zinc Transporter 8).

[!TIP] LADA (Latent Autoimmune Diabetes in Adults) Often misdiagnosed as "Type 2" initially. Clues:

• Age > 30 (but often less than 50).
• BMI less than 25 (Lean).
• Personal/Family history of autoimmunity (Target: Thyroid, Celiac, Vitiligo).
• "Secondary Failure": Rapid failure of Sulfonylureas/Metformin within months.
• Rx: Needs early insulin to preserve residual beta-cell mass.

Management: Lifestyle & Remission

Remission (The DiRECT Protocol)

The DiRECT Trial (2018) proved T2DM remission is possible.

• Definition: HbA1c less than 48 mmol/mol for > 3 months without medication.
• Target: 15kg weight loss.
• Mechanism: Removing ectopic fat from liver and pancreas ("De-clogging") permits beta-cell recovery.
• Method: Total Diet Replacement (TDR) phase (800 kcal/day soups/shakes) for 12 weeks, followed by food reintroduction.
• Success: ~46% remission at 1 year (86% if > 15kg lost).

Maintenance Diet

For those not on TDR:

• Mediterranean Diet: High evidence base. Plant-based, nuts, healthy fats (olive oil), fish.
• Low Carbohydrate: Effective for glycemic control. Caution with SGLT2i (Euglycemic DKA risk).

Pharmacotherapy: The Monographs

Modern guidelines (ADA/EASD, NICE NG28) prioritize Independent Risk Factors (Cardiovascular/Renal status) over HbA1c when choosing drugs.

1. Metformin

Class: Biguanide.

• Mechanism: Activates AMPK. Reduces hepatic gluconeogenesis. Increases muscle insulin sensitivity.
• Role: First-line universal therapy (unless contraindicated).
• Efficacy: Lowers HbA1c by 1.0-1.5%.
• Weight: Neutral or slight loss.
• Hypo Risk: Negligible.
• Dosing: Start 500mg OD with food. Titrate weekly to 1g BD. Max 2g/day.
• Adverse Effects:
  • GI: Diarrhea, bloating, nausea (very common). Use Modified Release (MR).
  • B12 Deficiency: Lowers absorption. Monitor annually.
  • Lactic Acidosis: Extremely rare. Associated with hypoxia/sepsis.
• ContraInd: eGFR less than 30 (Risk of accumulation). Stop during acute illness/contrast.

2. SGLT2 Inhibitors ("Gliflozins")

Agents: Dapagliflozin, Empagliflozin, Canagliflozin.

• Mechanism: Blocks SGLT2 in proximal tubule. Induces glucosuria (~70g/day) and natriuresis.
• Role:
  • First-line add-on for: Heart Failure, CKD, or ASCVD.
  • Independent of HbA1c: Give for organ protection even if HbA1c is at target.
• Efficacy: HbA1c 0.6-0.9%.
• Weight: Loss (~2-3kg due to calorie loss in urine).
• Cardiorenal Benefits:
  • HF: 30% reduction in hospitalization (DAPA-HF).
  • CKD: Slows progression to ESRD (DAPA-CKD, EMPA-KIDNEY).
• Adverse Effects:
  • Genital Thrush: Common. Treat with antifungals + hygiene.
  • Euglycemic DKA: Rare but dangerous. Must stop if unwell/fasting (Sick Day Rules).
  • Fournier's Gangrene: Rare necrotizing fasciitis of perineum.
• ContraInd: Pregnancy. Severe renal failure (initiation less than 20 ml/min).

3. GLP-1 Receptor Agonists ("Incretin Mimetics")

Agents: Semaglutide (Ozempic/Wegovy), Liraglutide (Victoza), Dulaglutide.

• Mechanism: Mimics GLP-1. Stimulates insulin (glucose-dependent), suppresses glucagon, slows gastric emptying, induces central satiety.
• Role:
  • First-line injectable.
  • Indications: BMI > 35, ASCVD, or failure of oral triple therapy.
• Efficacy: Potent. HbA1c 1.5-2.0%.
• Weight: Significant loss (5-15%).
• Adverse Effects:
  • GI: Nausea/Vomiting (common, transient). Titrate slow.
  • Retinopathy: "Early worsening" noted in SUSTAIN-6 (rapid glucose drop). Screen first.
  • Gallstones: Due to rapid weight loss.
• ContraInd: Hx of Pancreatitis. Medullary Thyroid Cancer (MEN2).

4. Tirzepatide (Twincretin)

Agent: Mounjaro.

• Mechanism: Dual GIP and GLP-1 receptor agonist. GIP enhances insulin secretion and lipid metabolism, synergizing with GLP-1.
• Role: NICE TA924. Valid option if triple therapy fails. Rivaling bariatric surgery efficacy.
• Efficacy: Superior to Semaglutide (SURPASS trials). HbA1c reduction > 2.0%.
• Weight: Weight loss > 20% possible.
• Adverse Effects: Similar GI profile to GLP-1s.

5. Sulfonylureas

Agents: Gliclazide, Glimepiride.

• Mechanism: Closes K-ATP channels on beta-cells -> Depolarization -> Insulin release. "Squeezes the pancreas".
• Role: Rapid symptom control. Second-line if Metformin intolerant and not obese.
• Pros: Cheap. Rapid onset.
• Cons:
  • Hypoglycemia: Major risk.
  • Weight Gain: 2-4kg.
  • Burnout: Secondary failure common.
• Choice: Gliclazide preferred (shorter half-life) over Glimepiride (long acting, higher hypo risk).

6. DPP-4 Inhibitors ("Gliptins")

Agents: Sitagliptin, Linagliptin.

• Mechanism: Inhibits breakdown of endogenous GLP-1.
• Role: Add-on if SGLT2i/GLP1/SU contraindicated. Safe in frailty.
• Pros: Placebo-like side effect profile. No hypos. Weight neutral.
• Cons: Weak efficacy (HbA1c ~0.5%). No CV/Renal outcome benefit.
• Note: Linagliptin needs no dose adjustment in renal failure.

7. Pioglitazone (Thiazolidinedione)

• Mechanism: PPAR-gamma agonist. Insulin sensitizer (Adipose > Muscle/Liver).
• Role: Effective in severe insulin resistance and NASH (Fatty Liver).
• Cons:
  • Fluid Retention: Precipitates Heart Failure. Contraindicated in any HF history.
  • Fractures: Increases distal bone fracture risk.
  • Bladder Ca: Unconfirmed but precautionary link.
  • Weight Gain: Significant (Fat redistribution + Fluid).

---

Insulin Management

Insulin is the ultimate replacement therapy.

1. Initiation Strategy (Basal-Only)

Usually strictly necessary when catabolic (ketones/weight loss) or symptomatic despite max orals.

• Continue: Metformin, SGLT2i (careful monitor), GLP-1 (good synergy).
• Stop: Sulfonylureas (usually), Pioglitazone.
• Choice:
  • NPH (Isophane): e.g., Humulin I. First line NICE. Cheap. Peak at 4-6 hours.
  • Analogue Basal: e.g., Lantus (Glargine), Levemir, Tresiba (Degludec). Flatter profile, less nocturnal hypo. Use if NPH causes hypos or lifestyle requires flexibility.
• Start Dose: 10 Units SC at bedtime (or morning if NPH).

2. Titration: The "3-0-3" Algorithm

Patient-led titration.

• Measure: Fasting Glucose (FPG) daily.
• Review: Every 3 Days.
• Action:
  • Avg FPG > Target (e.g., 7): +3 Units.
  • Avg FPG on Target: 0 Change.
  • Hypo (less than 4): -3 Units.

3. Intensification Regimens

If Basal is optimized (FPG less than 7) but HbA1c remains high -> Post-prandial spikes are the problem.

Option A: Basal-Plus

• Add 1 shot of Rapid-Acting (Novorapid) with largest meal ("Prandial spike buster").

Option B: Pre-Mix (Biphasic)

• Switch to BD Pre-mix (e.g., Novomix 30).
• Convenient (2 shots). Less flexible (must eat at fixed times).

Option C: Basal-Bolus (MDI)

• Basal + Rapid with every meal.
• Maximum flexibility ("Dose Adjustment for Normal Eating"

• DAFNE). High burden.

4. Injection Sites & Lipohypertrophy

• Sites: Abdomen (fast absorption), Thigh/Buttock (slow absorption).
• Lipohypertrophy: Fatty lumps at injection sites caused by insulin growth factor effect.
• Consequence: Erratic absorption (hypos/hypers).
• Prevention: Rotate sites systematically every injection.

Complications: The Annual Review

1. Diabetic Retinopathy

• Pathology: Microvascular occlusion and leakage.
• Screening: Annual Digital Photography.
• Treatment: Laser Photocoagulation (PRP) for proliferative. Anti-VEGF for maculopathy.

2. Diabetic Kidney Disease (DKD)

• Screening: ACR (Albumin-Creatinine Ratio) + eGFR.
  • ACR > 3 mg/mmol = Microalbuminuria.
  • ACR > 30 mg/mmol = Macroalbuminuria.
• KDIGO Heatmap: Risk stratified by G-stage (eGFR) and A-stage (Albuminuria).
• Management:
  • BP Control: Target less than 130/80.
  • RAAS Blockade: ACEi (Ramipril) or ARB (Losartan) mandated if ACR > 3 (with HTN) or > 30 (even if normotensive). Titrate to max.
  • SGLT2 Inhibition: Dapagliflozin/Empagliflozin mandated for CKD progression benefit.
  • Finerenone: Steroidal MRA added if significant albuminuria persists despite ACEi+SGLT2i.

3. Diabetic Neuropathy & Foot Care

• Sensory: Distal symmetrical polyneuropathy. Loss of protective sensation.
  • Rx for Pain: Duloxetine, Amitriptyline, Pregabalin, Capsaicin.
• Autonomic: Gastroparesis, ED, Orthostatic hypotension.
• The Diabetic Foot:
  • Risk Stratification:
    • Low Risk: Sensation intact, pulses palpable.
    • Moderate: Loss of sensation OR absent pulses.
    • High: Loss of sensation AND absent pulses / deformities.
    • Active: Ulceration / Infection / Charcot. -> MDFT Referral within 24hrs.
  • Charcot Arthropathy:
    • Acute: Hot, swollen, red foot. Painless (neuropathic).
    • Treatment: Total Contact Cast (Offloading) until heat resolves.

4. Cardiovascular Risk

• Overview: T2DM is a coronary risk equivalent.
• Lipids:
  • Primary Prevention: Atorvastatin 20mg (Q-Risk > 10% is almost universal).
  • Secondary Prevention: Atorvastatin 80mg.
• BP: Target less than 140/90 generally, less than 130/80 if renal involvement.

Special Situations

Driving (DVLA UK)

• Group 1 (Car):
  • Insulin: Must notify DVLA. Licence renewed every 1-3 yrs.
  • "5 to Drive": Test less than 2 hours before driving. Must be > 5.0. If less than 4.0, stop, treat, wait 45 mins.
  • Hypo Awareness: Must be intact.
  • Severe Hypos: If > 1 severe hypo (needing assist) in 12 months -> Licence revoked.
• Group 2 (HGV):
  • Strict. Insulin usually disqualifying unless 3 months of glucose logs on memory meter, full awareness, no severe hypos.

Steroid-Induced Hyperglycemia

• Steroids cause insulin resistance (post-prandial spike).
• Treat with morning Gliclazide or Morning NPH Insulin (matches steroid profile).
• Avoid basal-only regimens (risk of nocturnal hypo).

Pregnancy

• Pre-conception: Aim HbA1c less than 48. Folic Acid 5mg (High dose).
• Medications: Stop most orals (ACEi, Statins, SGLT2i, GLP1).
• Safe: Insulin, Metformin (usually).
• Targets: Tight control (Fasting less than 5.3, 1hr less than 7.8) to prevent macrosomia.

Clinical Vignettes

Case 1: The Metformin Ceiling

Scenario: 54M, T2DM 3 years. Metformin 1g BD. HbA1c 62. BMI 34. Analysis: Needs intensification. No CVD history. Plan:

1. Discuss weight.
2. Add SGLT2i (Dapagliflozin) or GLP-1 (if weight priority).
3. Avoid SU (weight gain).

Case 2: The Renal Decline

Scenario: 68F. T2DM, HTN. eGFR 35. ACR 40. On Metformin, Ramipril. Analysis: High risk of progression. Plan:

1. Dapagliflozin indicated for CKD (even if glucose controlled).
2. Ensure Ramipril optimized.
3. Monitor K+ and Creatinine (expect 20% dip in eGFR on starting SGLT2i/ACEi - hemodynamic effect, do not stop).

Case 3: The HGV Driver

Scenario: 45M Truck Driver. T2DM diagnosis. Analysis: Livelihood depends on avoidance of hypos/insulin. Plan:

1. Metformin -> SGLT2i -> DPP4i -> GLP1.
2. Avoid Gliclazide.
3. Avoid Insulin.

Case 4: The Fragile Elder

Scenario: 88F. Care home. Dementia. Recurrent falls. HbA1c 50. On Gliclazide 80mg BD. Analysis: Over-treated. High hypo risk contributing to falls. Plan:

1. De-intensify. Stop Gliclazide.
2. Accept HbA1c 65-75.
3. Switch to Linagliptin if needed (safe, no hypos).

References

1. Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2022. ADA/EASD Consensus. Diabetologia. 2022. [PMID: 36151309]
2. NICE NG28. Type 2 diabetes in adults: management. 2024.
3. KDIGO 2024. Clinical Practice Guideline for Diabetes in CKD.
4. McMurray JJV (DAPA-HF). N Engl J Med. 2019.
5. Marso SP (SUSTAIN-6). N Engl J Med. 2016.
6. Lean ME (DiRECT). Lancet. 2018.
7. DeFronzo RA. The Ominous Octet. Diabetes. 2009.
8. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998.

---

Appendix: Sick Day Rules

PATIENT HANDOUT: WHAT TO DO IF UNWELL (Vomiting, Diarrhea, Fever)

STOP (risk of dehydration/kidney injury):

• S - SGLT2 Inhibitors (Dapagliflozin, Empagliflozin) -> Risk of DKA.
• A - ACE inhibitors / ARBs (Ramipril, Losartan).
• D - Diuretics (Furosemide).
• M - Metformin (Risk of Lactic Acidosis - theoretical).
• AN - Anti-inflammatories (NSAIDs like Ibuprofen).

CONTINUE:

• Insulin (NEVER STOP INSULIN - you may need more due to stress).
  • Test glucose every 2-4 hours.
  • Check Ketones if glucose > 11.